OUR PURPOSE PIONEERING SCIENCE PATIENTS OUR PEOPLE ENVIRONMENT COMMUNITY REPORTING 35 BIOGEN 2021 YEAR IN REVIEW PATIENTS 100% of U.S. studies 1 initiated in 2021 included a plan to recruit underrepresented patients 1. U.S. clinical trials in Phases 1–4 led by Biogen’s Global Clinical Operations. Recipient of the Reuters Global Pharma Patient CHAMPION AWARD 65 COUNTRIES where SPINRAZA® is reimbursed Matilda was diagnosed with SMA Type 1 at the age of 11 months.